Plague, caused by the bacterium Yersinia pestis, is a disease that affects humans and other mammals. People typically get infected after being bitten by a rodent flea that is carrying the bacterium or by handling a plague-infected animal. Although the disease killed millions in Europe during the Middle Ages, antibiotics effectively treat plague today. Without prompt treatment, plague can cause serious illness or death. Human plague infections continue to occur in the western United States, but significantly more cases occur in parts of Africa and Asia.
Why Is the Study of Plague a Priority for NIAID?
Plague is a category A pathogen which are those organisms/biological agents that pose the highest risk to national security and public health because they can be easily disseminated or transmitted from person to person, result in high mortality rates and have the potential for major public health impact, might cause public panic and social disruption, and require special action for public health preparedness.
How Is NIAID Addressing This Critical Topic?
NIAID conducts and supports research on the diagnosis, prevention, and treatment of infections caused by microbes, including those that have the potential for use as biological weapons. The research program to address biodefense includes both short- and long-term studies targeted at designing, developing, evaluating, and approving specific tools (diagnostics, drugs, and vaccines) needed to defend against possible bioterrorist-caused disease outbreaks.
Latest News Releases
NIAID Releases Strategic Plan to Address Tuberculosis Research, September 26, 2018
NIH Launches Study to Test Combination Antibody Treatment for HIV Infection, September 20, 2018
Experimental Nasal Influenza Vaccine Tested in Kids, Teens, September 17, 2018
NIAID Now Blog
Festival Scenes: NIAID Science Featured at NIH Research Event, September 19, 2018
Video SNiP: PET Scan “Hot Spots” Help Visualize Inflammatory Complication of HIV, September 13, 2018
NIAID Research: The Director's Cut, August 27, 2018